Calcivis, an Edinburgh, Scotland, UK-based medical devices company focused on the management of tooth decay and enabling preventive dentistry, closed the final part of a £4.5m equity funding round.
The round was led by Archangels, which was supported by the Scottish Investment Bank.
The proceeds will be used to support the company’s development as it anticipates Pre-Market Approval (PMA) of the CALCIVIS® Imaging System from FDA in the US. Calcivis plans the launch its imaging system in the US in 2020, subject to the PMA being approved.
Launched in 2012 and led by Adam Christie, CEO, Calcivis provides an imaging system enables dental practitioners to offer bespoke, evidence-based preventive treatment for dental caries patients.
The imaging system provides visual evidence of demineralization at an early stage. It means dentists can differentiate between active and non-active lesions on tooth surfaces, allowing them to monitor the condition of tooth enamel accurately and effectively over time.
The company has raised equity and grant funding totalling over £14m since its inception.